CSPC Pharmaceutical Group Limited: Carcinoma, Non-Small-Cell Lung trials

The registry lists 20 Carcinoma, Non-Small-Cell Lung studies with CSPC Pharmaceutical Group Limited as lead sponsor. 14 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 10Phase 3 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07672223Phase 3
• SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）Not yet recruitingNCT07633873Phase 3
• SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingNCT07472647Phase 1/2
• SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase ⅢNot yet recruitingNCT07442565Phase 3
• A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerNot yet recruitingNCT07256509Phase 2
• Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）RecruitingNCT06927986Phase 3
• Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNot yet recruitingNCT06908772Phase 2/3
• A Study of JMT203 in Patients With Cancer CachexiaRecruitingNCT06868849Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsRecruitingNCT06829459Phase 3
• A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsRecruitingNCT06735391Phase 3
• A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung CancerNot yet recruitingNCT06525350Phase 2
• JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNot yet recruitingNCT06380348Phase 3
• Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNot yet recruitingNCT06319313Phase 2/3
• A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT05863325Phase 2
• JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruitingNCT06391944Phase 2
• Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerStatus unknownNCT05513664
• Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerStatus unknownNCT05132777Phase 2
• Study of HA121-28 in Patients With Non-Small Cell Lung CancerStatus unknownNCT05117658Phase 2
• Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownNCT04448379Phase 1
• Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung CancerStatus unknownNCT03262948Phase 3